// App-Quantinova.ai

2112 : Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

Researchers

Presenter

  • Christopher Ritchlin

Principal Investigators

  • Philip J Mease

  • Wolf-Henning Boehncke

  • John Tesser

  • Soumya Chakravarty

  • Emmanouil Rampakakis

  • May Shawi

  • Elena Schiopu

  • Joseph Merola

  • Iain B McInnes

  • Atul Deodhar

Medical Centers

  • Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY

  • Swedish Medical Center/Providence St. Joseph Health, Seattle, WA

  • Deptartment of Dermatology, Geneva University Hospitals, University of Geneva, Geneva, Switzerland

  • Arizona Arthritis & Rheumatology Associates, Glendale, AZ, United States

  • Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA

  • McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada

  • Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, USA

  • Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI

  • Brigham and Women's Hospital and Harvard Medical School, Boston, MA

  • Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom

  • Oregon Health & Science University, Portland, OR, USA, Portland, OR

Locations

  • United States

  • Switzerland

  • Canada

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • C reactive protein

  • Malondialdehyde

  • Body mass index

  • Albumin/creatinine

Drug/Treatment

  • Methotrexate

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Cross Over

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved